Glenmark Pharmaceuticals has announced the launch of RYALTRIS Nasal Spray in Brazil for treating moderate to severe symptoms associated with allergic rhinitis in adults and adolescents aged 12 years and older. According to reports from Business Standard, the launch follows regulatory approval granted by the Brazilian Health Regulatory Agency, Agencia Nacional de Vigilancia Sanitia (ANVISA) earlier this year. As per Glenmark Pharmaceuticals, this strategic launch marks a significant milestone in the company's expanding global respiratory innovation portfolio and strengthens its presence in Latin America.
The launch addresses a significant medical need in Brazil, where allergic rhinitis affects an estimated 20-30% of the population, equivalent to nearly 40-60 million people. As reported by Business Standard, this substantial disease burden highlights the urgent need for effective, convenient, and differentiated treatment options for patients across the country. The condition represents a highly prevalent chronic condition in Brazil that requires specialized medical interventions.
The launch introduces the first olopatadine-containing intranasal combination therapy in Brazil, combining an antihistamine (olopatadine hydrochloride) and a corticosteroid (mometasone furoate) in a single nasal spray. According to Glenmark Pharmaceuticals, this dual-action approach offers a convenient and effective solution for patients suffering from allergic rhinitis symptoms. The product represents Glenmark's first globally commercialized branded innovative product and has already received approvals in 57 markets worldwide, including the United States, European Union, United Kingdom, Australia, South Korea, Russia, and China.
The launch reflects Glenmark's continued commitment to advancing its respiratory innovation journey and reinforces the company's progress in expanding access to differentiated therapies across global markets. As reported by Business Standard, this strategic move demonstrates the company's focus on bringing innovative respiratory solutions to underserved markets where chronic conditions like allergic rhinitis pose significant healthcare challenges. Marco Cerato, Executive Vice President & Global Head – Innovative Business at Glenmark Pharmaceuticals, commented on the launch, stating, "The launch of RYALTRIS® in Brazil marks a significant milestone for our innovative respiratory portfolio and reflects our continued commitment to advancing respiratory care through science-led innovation and a patient-centric approach."
